The Alabama Board of Health recently proposed a rule that would change ALPRAZolam from a schedule IV to a schedule II medication, with plans to become effective in late April. This step would have caused numerous problems with labeling, storage, wholesalers, drug shortages, illicit drug diversion/abuse, mental health patient access to drug, and others. Alabama pharmacy organizations spoke out to legislators against the CII scheduling. On April 13^th, the state legislative council met and considered both sides to this issue, and voted NOT to change the drug to CII. ALPRAZolam will remain a schedule IV drug in Alabama.